The pharmaceutical group is asking its shareholders to approve a performance-based deal that could hand Pascal Soriot (pictured) up to £18.7m this year.
The pharmaceutical group is asking its shareholders to approve a performance-based deal that could hand Pascal Soriot (pictured) up to £18.7m this year.